Alpa Laboratories Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has delivered good profit growth of 37.0% CAGR over last 5 years
- Company is almost debt free
- Company comfortably covers its interest (98.0x coverage)
- Company generates healthy free cash flow
CONS
- Recent results are weak - TTM profit is down 77.5% versus prior year
- A large part of profit comes from other income (90.2% of PBT)
- Operating margins have contracted to 4.5% from 19.1%
- Company has delivered a poor sales growth of 5.5% over past five years
- Growth is decelerating - 3Y profit CAGR (11.7%) trails the 5Y trend (37.0%)
- Expensive relative to growth - PEG of 2.5
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| ALPA | 61.85 | 29.73 | 130.14 | 0.00 | 0.98 | -91.67 | 23.93 | 25.23 | 15.76 | -16.54 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 | 32 | 27 | 24 | 21 | 25 | 26 | 39 | 19 | 26 | 30 | 31 | 24 | |
| 27 | 29 | 25 | 20 | 21 | 22 | 25 | 39 | 19 | 28 | 28 | 28 | 29 | |
| Operating Profit | -1 | 3 | 2 | 4 | 1 | 3 | 1 | -0 | 0 | -3 | 2 | 4 | -5 |
| OPM % | -4.52% | 10.22% | 9.01% | 14.91% | 2.52% | 13.11% | 2.83% | -0.92% | 2.20% | -11.20% | 7.18% | 11.50% | -20.02% |
| 4 | 3 | 4 | 4 | 5 | 7 | 9 | 3 | 12 | 4 | 0 | -0 | 6 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| Profit before Tax | 3 | 6 | 5 | 7 | 5 | 10 | 9 | 2 | 12 | 0 | 2 | 3 | 1 |
| Tax % | 0.00% | 0.00% | 14.85% | 46.70% | 0.00% | 20.44% | 0.00% | 186.67% | 0.00% | 0.00% | -9.30% | 55.41% | 0.00% |
| Net Profit | 3 | 6 | 5 | 4 | 5 | 8 | 9 | -2 | 12 | 0 | 2 | 1 | 1 |
| 1.44 | 2.75 | 2.14 | 1.70 | 2.44 | 3.63 | 4.24 | -0.93 | 5.60 | 0.05 | 0.89 | 0.64 | 0.52 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 54 | 63 | 62 | 78 | 86 | 98 | 112 | 93 | 109 | 112 | 111 | |
| 47 | 56 | 58 | 77 | 83 | 90 | 102 | 85 | 101 | 107 | 113 | |
| Operating Profit | 6 | 7 | 4 | 1 | 3 | 8 | 11 | 8 | 8 | 5 | -2 |
| OPM % | 11.67% | 11.21% | 6.35% | 1.57% | 4.02% | 7.90% | 9.52% | 8.69% | 7.49% | 4.45% | -1.74% |
| 7 | 4 | 5 | 5 | 3 | 4 | 11 | 9 | 15 | 23 | 10 | |
| Interest | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 |
| Profit before Tax | 11 | 9 | 7 | 5 | 5 | 11 | 20 | 16 | 21 | 26 | 6 |
| Tax % | 27.20% | 34.24% | 27.25% | 36.20% | 19.68% | 32.69% | 27.86% | 20.76% | 18.85% | 23.84% | 25.89% |
| Net Profit | 8 | 6 | 5 | 3 | 4 | 7 | 14 | 13 | 17 | 20 | 4 |
| EPS | 0.00 | 2.85 | 0.00 | 0.00 | 0.00 | 3.46 | 6.71 | 0.00 | 7.97 | 9.35 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 7%
- 5 Years:
- 6%
- 3 Years:
- 0%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- 37%
- 3 Years:
- 12%
STOCK PRICE CAGR
- 10 Years:
- 7%
- 5 Years:
- 3%
- 3 Years:
- -5%
- 1 Year:
- -35%
RETURN ON EQUITY
- 10 Years:
- 8%
- 5 Years:
- 10%
- 3 Years:
- 10%
- Last Year:
- 11%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| 73 | 77 | 82 | 85 | 89 | 96 | 111 | 124 | 141 | 161 | |
| 25 | 11 | 6 | 1 | 0 | 0 | 4 | 1 | 4 | 0 | |
| Trade Payables | 19 | 14 | 13 | 13 | 14 | 25 | 15 | 15 | 12 | 19 |
| 9 | 5 | 4 | 8 | 6 | 8 | 14 | 17 | 14 | 32 | |
| Total Liabilities | 147 | 128 | 126 | 129 | 130 | 150 | 165 | 178 | 192 | 233 |
| 5 | 5 | 6 | 6 | 6 | 7 | 9 | 7 | 11 | 21 | |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| 22 | 23 | 41 | 59 | 68 | 62 | 86 | 89 | 109 | 129 | |
| 15 | 13 | 14 | 14 | 13 | 17 | 15 | 13 | 14 | 18 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 | 47 | |
| Cash & Bank | 35 | 36 | 21 | 1 | 6 | 10 | 1 | 9 | 1 | 2 |
| 71 | 51 | 43 | 48 | 37 | 53 | 53 | 61 | 16 | 17 | |
| Total Assets | 147 | 128 | 126 | 129 | 130 | 150 | 165 | 178 | 192 | 233 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -22 | -5 | -6 | 1 | 19 | 1 | 6 | 14 | 4 | 18 | |
| Cash from Investing | -7 | 1 | -16 | -15 | -11 | 6 | -16 | 1 | -12 | -12 |
| Cash from Financing | -6 | -2 | 4 | -5 | -1 | -0 | 5 | -3 | 2 | -5 |
| -37 | -9 | -19 | -20 | 5 | 4 | -8 | 8 | -6 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-07 - Alpa Laboratories Limited has informed the Exchange that Record date for the purpose of Meeting is 22-Sep-2026.
2026-09-07 - Alpa Laboratories Limited has informed the Exchange regarding Appointment of Mrs RADHIKA as Non- Execut of the company w.e.f. September 05, 2026.
2026-08-13 - Alpa Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-11 - Alpa Laboratories Limited has informed the Exchange regarding 'clarification board meeting date'.
2026-07-29 - Alpa Laboratories Limited has informed the Exchange about General Updates
2026-07-27 - The Exchange had sought clarification from Alpa Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
2026-07-22 - Alpa Laboratories Limited has informed the Exchange regarding Cessation of Ms.Jyoti Jain as Non- Executive Independent Director of the company w.e.f. July 21, 2026.
2026-07-08 - Alpa Laboratories Limited has informed the Exchange regarding Cessation of Ms Yashoda Patidar as Company Secretary & Compliance Officer of the company w.e.f. July 26, 2026.
2026-06-25 - Alpa Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
News
Recent coverage and analyst commentary for ALPA
Loading news…
AI Stock Analyst
Alpa Laboratories Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account